☰

cached image

Shaomeng Wang

Affiliations: 
1986-1992 chemistry University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Molecular Therapeutics
Website:
http://sw16.im.med.umich.edu/
Google:
"Shaomeng Wang"
Bio:

Dr. Wang received his B.S. in Chemistry from Peking University in 1986 and his Ph.D. in Chemistry from Case Western Reserve University in 1992. Dr. Wang did his postdoctoral training in drug design at the National Cancer Institute, NIH between1992-1996. Dr. Wang was Assistant Professor at Georgetown University from 1996-2000 and Associate Professor from 2000-2001. Dr. Wang joined the faculty at the University of Michigan Medical School as a tenured Associate Professor in 2001 and was promoted to Professor in 2006. Dr. Wang was named the Warner-Lambert/Parke-Davis Professor in Medicine in 2007. Dr. Wang serves as the Co-Director of the Molecular Therapeutics Program at the University of Michigan Comprehensive Cancer Center and is the Director of the Cancer Drug Discovery Program at the University of Michigan.

Mean distance: 9.25
 		SNBCP
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Gilles Klopman grad student 1986-1992 University of Michigan

Children

Sign in to add trainee
jian zhang grad student
Yipin Lu grad student 2006 University of Michigan
Yuefeng Peng grad student 2008 University of Michigan
Cindy A. Gomez grad student 2009 University of Michigan
Steven A. Kawamoto grad student 2010 University of Michigan
Hacer Karatas grad student 2012 University of Michigan
Xu Ran grad student 2010-2014 University of Michigan

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Zhao L, Han X, Lu J, et al. (2020) A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo. Neoplasia (New York, N.Y.). 22: 522-532
Barcherini V, Almeida J, Lopes E, et al. (2020) Potency and selectivity optimization of tryptophanol-derived oxazoloisoindolinones: novel p53 activators in human colorectal cancer. Chemmedchem
Rej RK, Wang C, Lu J, et al. (2020) EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. Journal of Medicinal Chemistry
Chern TR, Liu L, Petrunak E, et al. (2020) Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase. Acs Medicinal Chemistry Letters. 11: 1348-1352
Wang M, Lu J, Wang M, et al. (2020) Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein. Journal of Medicinal Chemistry
Xu S, Aguilar A, Huang L, et al. (2020) Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong Antitumor Activity. Journal of Medicinal Chemistry
Zong D, Gu J, Cavalcante GC, et al. (2020) BRD4 levels determine the response of human lung cancer cells to BET degraders that potently induce apoptosis through suppression of Mcl-1. Cancer Research
Zhou H, Lu J, Yang CY, et al. (2020) Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway. Advances in Experimental Medicine and Biology. 1217: 349-362
Chen J, Wu C, Jiao L, et al. (2020) Abstract 73: Development of APG-3526 as a novel and highly efficacious MCL-1 inhibitor Cancer Research. 80: 73-73
Kregel S, Wang C, Han X, et al. (2020) Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment Cancer Research. 80: 5679-5679
See more...